New, Cost-Effective Surgical Tools to Drive Ophthalmological Surgery Says Frost & Sullivan
Posted Under: Studies
New, Cost-Effective Surgical Tools to Drive Ophthalmological Surgery Says Frost & Sullivan
Mountain View, CA, United States, 09/01/2009 – New analysis from Frost & Sullivan, Innovative Surgical Devices for Human Vision Disorders, finds that the ophthalmology medical devices market is growing dynamically at present and is anticipated to continue with this growth trend.
The ophthalmology medical devices industry currently represents a dynamic industrial sector in which devices that enable minimally invasive surgery will show substantial growth, especially as these procedures have become the norm for more individualized treatments.
Implantable ophthalmologic medical devices offer scientific challenges that are undoubtedly difficult, although not impossible, with the path to success already discernible. Moreover, severe eye disorders are debilitating, but not terminal.
New analysis from Frost & Sullivan (technicalinsights.frost.com), Innovative Surgical Devices for Human Vision Disorders, finds that the ophthalmology medical devices market is growing dynamically at present and is anticipated to continue with this growth trend over the next three to four years.
If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an email to Jake Wengroff, Corporate Communications, at jake.wengroff[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country.
“An emerging trend in the ophthalmological surgical devices industry is the increased attention towards various sub-types of eye disease clusters – the main driver for innovations,” notes Technical Insights Senior Research Analyst Prasanna Vadhana Kannan. “The awareness generated about the unique advantages of such surgeries amongst patients is paving the way for immense growth in the implantable devices market.”
A wide gamut of ophthalmic diseases, including age-related macular degeneration (AMD), cataracts, glaucoma, and dry eye syndromes have resulted in potentially compromised vision and debilitating vision loss. An aging population, changing lifestyles, and a highly demanding working environment leading to stress in the eyes are impelling healthcare officials to opt for ophthalmic-related diagnosis and surgical treatment to improve, restore, and preserve sight. Within the next few years, the implantable devices sector is anticipated to grow dramatically, superseding the market share of contact lenses, glasses, and ophthalmologic drugs.
The dearth of patient compliance data and the requirement for effective training programs for surgeons and physicians have increased. There has been a surge in innovation in terms of both devices as well as the procedural levels in the ophthalmological surgical devices market.
Surgeries have gradually shifted from being invasive to non-invasive, causing less trauma to the patient. The launch of such novel technologies has necessitated that ophthalmologic surgeons undergo frequent training even while existing systems are continuously upgraded. For hospital authorities, the introduction of novel products demands greater investment, posing a key challenge in conditions where there are healthcare budgetary constraints.
The current ophthalmological surgical devices industry trend is towards newer products based on innovative technologies such as accommodative lenses, implantable retinal prosthetics, and laser in situ keratomileusis (LASIK). These have largely replaced the widespread utilization of conventional treatment approaches.
“Intensive research is underway to effectually analyze the biocompatibility of these novel treatments along with the strengthening power needed to repair visual disorders with minimal side effects, all at lower costs,” remarks Kannan. “However, investigations done by researchers have failed to examine patient compliance to the novel treatment approaches that have been developed.”
The ophthalmic surgical devices market being highly segmented, product suite expansion is the key factor for all major multinational firms to exhibit growth.
“By harnessing nanotechnology breakthroughs, tissue engineering, and regenerative medicine constructs, along with a combination of unique molecular diagnostic tools, researchers are now equipped with a wide range of opportunities for taking ophthalmic surgical treatments to the next level,” concludes Kannan. “This next level will transform ophthalmic surgical interventions from generalized therapies to highly personalized medicine.”
Innovative Surgical Devices for Human Vision Disorders, a part of the Technical Insights subscription, provides a technology overview and outlook for the surgical devices for human vision disorders technology. The study provides identification of key areas where research efforts should be directed and guide in developing blindness prevention strategies. Further, this research service includes detailed technology analysis and industry trends evaluated following extensive interviews with market participants.
Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents.
